These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

91 related articles for article (PubMed ID: 27748542)

  • 1. Postexposure prophylaxis with intravenous immunoglobulin G prevents infants from getting measles.
    Lejeune A; Martin L; Santibanez S; Thee S; Gratopp A; Späth P; Mankertz A; Kallinich T; von Bernuth H
    Acta Paediatr; 2017 Jan; 106(1):174-177. PubMed ID: 27748542
    [No Abstract]   [Full Text] [Related]  

  • 2. Current efficacy of postexposure prophylaxis against measles with immunoglobulin.
    Endo A; Izumi H; Miyashita M; Taniguchi K; Okubo O; Harada K
    J Pediatr; 2001 Jun; 138(6):926-8. PubMed ID: 11391343
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Measles in a mother and her newborn baby.
    Peruzzo M; Giannini O; Bianchetti MG
    Arch Dis Child; 2012 Jul; 97(7):660. PubMed ID: 22493404
    [No Abstract]   [Full Text] [Related]  

  • 4. Immunity to measles during pregnancy.
    Wallace MR; Hooper DG
    Clin Infect Dis; 1992 Jun; 14(6):1262-3. PubMed ID: 1623085
    [No Abstract]   [Full Text] [Related]  

  • 5. Postexposure prophylaxis, isolation, and quarantine to control an import-associated measles outbreak--Iowa, 2004.
    Centers for Disease Control and Prevention (CDC)
    MMWR Morb Mortal Wkly Rep; 2004 Oct; 53(41):969-71. PubMed ID: 15496826
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Feasibility of identifying plasma donors with high measles neutralizing antibody concentrations for the use of producing a measles hyperimmune globulin for postexposure prophylaxis.
    Lackner C; Karbiener M; Faltner L; Farcet MR; Kreil TR
    Immunol Res; 2022 Jun; 70(3):365-370. PubMed ID: 35266077
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Protecting infants against measles in England and Wales: a review.
    Manikkavasagan G; Ramsay M
    Arch Dis Child; 2009 Sep; 94(9):681-5. PubMed ID: 19457878
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The effectiveness of prophylaxis for measles contacts in NSW.
    Sheppeard V; Forssman B; Ferson MJ; Moreira C; Campbell-Lloyd S; Dwyer DE; McAnulty JM
    N S W Public Health Bull; 2009; 20(5-6):81-5. PubMed ID: 19552854
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Two cases of Guillain-Barré syndrome during measles elimination campaign in Izmir.
    Koturoglu G; Kurugol Z; Tekgul H; Ozcan T; Dizdarer C
    Minerva Pediatr; 2008 Dec; 60(6):1455-7. PubMed ID: 18971907
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Measles outbreak--Ungava region, Quebec.
    De Serres G; Boulianne N
    Can Dis Wkly Rep; 1991 Oct; 17(42):229-31. PubMed ID: 1790576
    [No Abstract]   [Full Text] [Related]  

  • 11. Measles outbreak--Washington, 1989: failure of delayed postexposure prophylaxis with vaccine.
    Centers for Disease Control (CDC)
    MMWR Morb Mortal Wkly Rep; 1990 Sep; 39(36):617-9. PubMed ID: 2118587
    [No Abstract]   [Full Text] [Related]  

  • 12. Management of infants whose mothers have measles.
    Halsey NA; Hughart N; Holt E; Guyer B
    Pediatrics; 1994 May; 93(5):872. PubMed ID: 8165106
    [No Abstract]   [Full Text] [Related]  

  • 13. Incomplete Kawasaki disease induced by measles in a 6-month-old male infant.
    Hu P; Guan Y; Fan XC; Lu FY; Song LM
    Int J Dermatol; 2016 Jan; 55(1):e34-6. PubMed ID: 26518488
    [No Abstract]   [Full Text] [Related]  

  • 14. [Polyvalent immunoglobulins in prevention of viral infections in children with neoplastic diseases treated with immunosuppressive therapy].
    Graf N; Hille A; Jost W; Müller J
    Padiatr Padol; 1991; 26(4):187-91. PubMed ID: 1749627
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Measles in mother-infant pairs.
    Darmstadt GL; Halsey NA
    Pediatr Infect Dis J; 1992 Jun; 11(6):492-3. PubMed ID: 1608688
    [No Abstract]   [Full Text] [Related]  

  • 16. Measles virus transmission from infected to immune individuals--implications for measles control and elimination.
    Vardas E; Andre M; Kreis S; Zachariades N; Schoub B
    S Afr Med J; 1997 Dec; 87(12):1709. PubMed ID: 9497848
    [No Abstract]   [Full Text] [Related]  

  • 17. Early waning of maternal measles antibodies in era of measles elimination: longitudinal study.
    Leuridan E; Hens N; Hutse V; Ieven M; Aerts M; Van Damme P
    BMJ; 2010 May; 340():c1626. PubMed ID: 20483946
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Measles vaccination effectiveness among children under 5 years of age in Kampala, Uganda.
    Mupere E; Karamagi C; Zirembuzi G; Grabowsky M; de Swart RL; Nanyunja M; Mayanja H
    Vaccine; 2006 May; 24(19):4111-5. PubMed ID: 16554111
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The use of intravenous immunoglobulins in Belgium.
    Simoens S
    Int Arch Allergy Immunol; 2011; 154(2):173-6. PubMed ID: 20733326
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Increase of immunoglobulins G, A, M, D and specific antibodies in a group of children vaccinated against measles by Czechoslovak live vaccine Movivac Sevac].
    Wiedermannová D; Wiedermann D; Bozdĕchová M; Hatiarová Z
    Cas Lek Cesk; 1973 Mar; 112(10):297-301. PubMed ID: 4691543
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.